The Federal Register Notice promulgating the proposed Attributable Owner rules offers some lofty justifications for the rules. Because the rules have been promulgated pursuant to a White House initiative, they are likely to take effect in some form, but applicants and stakeholders should not miss the opportunity to submit comments and suggestions to the USPTO in an effort to make the final rules less onerous. Continue reading this entry
In a Federal Register Notice published March 27, 2014, the USPTO announced a Glossary Pilot Program that will offer expedited examination to new patent applications in certain technology areas that include a glossary of terms that meets certain formal requirements. The program will commence on June 2, 2014, and run for six months or until the USPTO accepts 200 applications into the program (whichever comes first). Continue reading this entry
In his State of the Union Address given on January 28, 2014, President Obama recognized the need for continued and increased investment in new technologies, including technologies specific to the biological and pharmaceutical fields.
In Mohsenzadeh v. Lee (decided March 19, 2014), the U.S. District Court for the Eastern District of Virginia held that the Patent Term Adjustment (PTA) statute does not provide PTA to a divisional application when the USPTO takes longer than 14 months to issue a Restriction Requirement in the parent application. While this decision is not surprising, it is a reminder that applicants may have to choose between the protections offered to divisional applications by 35 USC § 121 and the possible impact on enforceable patent term of filing related applications in series rather than in parallel. Continue reading this entry
The USPTO has set up a new web page with resources for examining claims for patent subject matter eligibility, including a link to the slides used in training programs for Examiners in Technology Centers 1600 and 1700. While the slides hew closely to the Guidelines, they include additional commentary and examples that illustrate how the Guidelines might be applied in practice. One new example in particular feeds my concerns about the patent eligibility of pharmaceutical compositions under the Guidelines, and highlights where the USPTO’s interpretation of Supreme Court jurisprudence may have gone awry. Continue reading this entry